TY  - JOUR
AU  - Ruiz-Villaverde, Ricardo
AU  - Rodriguez Fernandez-Freire, Lourdes
AU  - Font-Ugalde, Pilar
AU  - Galan-Gutierrez, Manuel
PY  - 2022
DO  - 10.3390/jcm11175098
SN  - 2077-0383
UR  - http://hdl.handle.net/10668/21343
T2  - Journal of clinical medicine
AB  - Tildrakizumab (TIL) binds selectively to the p19 subunit of interleukin 23. Its introduction has managed to increase the levels of efficacy, safety (improving that previously presented by the anti-IL-12/23 class) and survival. Retrospective analysis...
LA  - en
PB  - MDPI
KW  - Biological therapy
KW  - Psoriasis
KW  - Treatment
KW  - Arthritis, psoriatic
KW  - Tildrakizumab
KW  - Interleukin-23
KW  - Interleukin-12
KW  - Scalp
KW  - Retrospective studies
KW  - Spain
KW  - Tertiary care centers
KW  - Psoriasis
KW  - Biological therapy
TI  - Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks) in Three Tertiary Hospitals in Andalucia (Spain).
TY  - research article
VL  - 11
ER  -